Morphic to Present at 2022 Jefferies Global Healthcare Conference

Rhea-AI Summary

Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company focused on oral integrin therapies for chronic diseases, announced a presentation by President Bruce Rogers, Ph.D., at the Jefferies Global Healthcare Conference on June 9, 2022, at 2:00 PM ET. The event will be streamed live on Morphic's investor website, with an archived replay available afterward. Morphic is collaborating with industry leaders like AbbVie and Janssen to advance its pipeline using its proprietary MInT technology platform, targeting conditions such as autoimmune diseases, cardiovascular issues, and cancer.

WALTHAM, Mass., June 09, 2022 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that Bruce Rogers, Ph.D., President of Morphic, will give a corporate presentation at the Jefferies Global Healthcare Conference on Thursday, June 9^th at 2:00 PM ET.

A live webcast of the event will be available on the Investor section of Morphic’s website at www.morphictx.com. An archived replay will be available on the company’s website following the conference.

About Morphic Therapeutic

Morphic Therapeutic is a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, including autoimmune, cardiovascular, and metabolic diseases, fibrosis, and cancer. In collaboration with AbbVie, Janssen, and Schrödinger, Morphic is advancing its pipeline and discovery activities using its proprietary MInT technology platform which leverages the Company’s unique understanding of integrin structure and biology. For more information, visit www.morphictx.com.

Contacts
Morphic Therapeutic
Chris Erdman
chris.erdman@morphictx.com
617.686.1718

FAQ

What will Bruce Rogers discuss at the Jefferies Global Healthcare Conference on June 9, 2022?

Bruce Rogers will present information about Morphic Therapeutic's developments in oral integrin therapies for chronic diseases.

How can I watch the Morphic Therapeutic presentation on June 9, 2022?

The presentation can be viewed live on Morphic Therapeutic's investor website, with an archived replay available after the event.

What are the main diseases Morphic Therapeutic's therapies target?

Morphic Therapeutic focuses on treating serious chronic diseases, including autoimmune, cardiovascular, metabolic diseases, and cancer.

What technology platform does Morphic Therapeutic use?

Morphic Therapeutic utilizes its proprietary MInT technology platform to advance its drug development initiatives.

Which companies is Morphic Therapeutic collaborating with?

Morphic Therapeutic is collaborating with AbbVie, Janssen, and Schrödinger to enhance its pipeline and discovery activities.